Immunocore reports early data showing 70% two-year survival with brenetafusp/Kimmtrak combo in uveal melanoma

Immunocore presented early clinical data on its bispecific T-cell engager combination brenetafusp and Kimmtrak in patients with uveal melanoma.

The analysis, based on a subset of patients, indicated an estimated 70% overall survival at two years after treatment, suggesting durable benefit.

The results are preliminary and derived from an early-stage study, but they highlight the potential of dual T-cell engager strategies in a cancer type with limited therapeutic options.

Immunocore plans further evaluation in larger trials to confirm efficacy and safety.